

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number: 3235-0104

Estimated average burden

hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934  
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>IDEX CORP /DE/</u>	2. Date of Event Requiring Statement (Month/Day/Year) <u>02/25/2011</u>	3. Issuer Name and Ticker or Trading Symbol <u>MICROFLUIDICS INTERNATIONAL CORP [ MFLU.OB ]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year) <u>03/01/2011</u>
(Last) (First) (Middle) <u>1925 WEST FIELD COURT, SUITE 200</u>			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person
(Street) <u>LAKE FOREST IL 60045</u>			
(City) (State) (Zip)			

## Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

## Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
<u>9% Convertible Debenture</u>	<u>(1)</u>	<u>11/14/2015</u>	<u>Common Stock</u>	<u>4,192,890<sup>(2)(3)</sup></u>	<u>1.25</u>	<u>D</u>	

## Explanation of Responses:

1. The debenture is convertible on the maturity date (November 14, 2015), any interest payment date (the first business day of each calendar quarter) or the date of a change of control event (as defined in the debenture), at the written election of the holder and upon three business days' notice to Microfluidics International Corporation.

2. IDEX Corporation ("IDEX"), Nano Merger Sub, Inc. (a wholly-owned subsidiary of IDEX), Global Strategic Partners, LLC ("GPS"), Abraxis BioScience, LLC and American Stock Transfer and Trust Company, LLC, in its capacity as custodian, entered into an Agreement Concerning Debenture, dated January 10, 2011 (the "Agreement Concerning Debenture"), pursuant to which, on February 25, 2011, IDEX purchased the debenture from GPS for approximately \$4.2 million, and the debenture was assigned and transferred to IDEX.

3. These shares were omitted from the Reporting Person's initial Form 3.

IDEX Corporation, by /s/  
Frank J. Notaro, Vice President 03/07/2011  
and General Counsel

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.